These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21550404)

  • 61. Innate and adaptive immune activation in the brain of MPS IIIB mouse model.
    DiRosario J; Divers E; Wang C; Etter J; Charrier A; Jukkola P; Auer H; Best V; Newsom DL; McCarty DM; Fu H
    J Neurosci Res; 2009 Mar; 87(4):978-90. PubMed ID: 18951493
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.
    Duncan FJ; Naughton BJ; Zaraspe K; Murrey DA; Meadows AS; Clark KR; Newsom DE; White P; Fu H; McCarty DM
    Mol Ther; 2015 Apr; 23(4):638-47. PubMed ID: 25592334
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Long-term safety and clinical outcomes of intrathecal heparan-N-sulfatase in patients with Sanfilippo syndrome type A.
    Wijburg FA; Heap F; Rust S; de Ruijter J; Tump E; Marchal JP; Nestrasil I; Shapiro E; Jones SA; Alexanderian D
    Mol Genet Metab; 2021 Dec; 134(4):317-322. PubMed ID: 34600820
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases.
    Hemsley KM; Hopwood JJ
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1():S118-23. PubMed ID: 20040322
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: the positive effect of long-term aspirin treatment.
    Arfi A; Richard M; Gandolphe C; Bonnefont-Rousselot D; Thérond P; Scherman D
    Mol Genet Metab; 2011 May; 103(1):18-25. PubMed ID: 21353610
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I.
    Kakkis E; McEntee M; Vogler C; Le S; Levy B; Belichenko P; Mobley W; Dickson P; Hanson S; Passage M
    Mol Genet Metab; 2004; 83(1-2):163-74. PubMed ID: 15464431
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB.
    Kan SH; Aoyagi-Scharber M; Le SQ; Vincelette J; Ohmi K; Bullens S; Wendt DJ; Christianson TM; Tiger PM; Brown JR; Lawrence R; Yip BK; Holtzinger J; Bagri A; Crippen-Harmon D; Vondrak KN; Chen Z; Hague CM; Woloszynek JC; Cheung DS; Webster KA; Adintori EG; Lo MJ; Wong W; Fitzpatrick PA; LeBowitz JH; Crawford BE; Bunting S; Dickson PI; Neufeld EF
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14870-5. PubMed ID: 25267636
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB.
    Ellinwood NM; Valentine BN; Hess AS; Jens JK; Snella EM; Jamil M; Hostetter SJ; Jeffery ND; Smith JD; Millman ST; Parsons RL; Butt MT; Chandra S; Egeland MT; Assis AB; Nelvagal HR; Cooper JD; Nestrasil I; Mueller BA; Labounek R; Paulson A; Prill H; Liu XY; Zhou H; Lawrence R; Crawford BE; Grover A; Cherala G; Melton AC; Cherukuri A; Vuillemenot BR; Wait JCM; O'Neill CA; Pinkstaff J; Kovalchin J; Zanelli E; McCullagh E
    J Pharmacol Exp Ther; 2022 Sep; 382(3):277-286. PubMed ID: 35717448
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Comparative analysis of brain pathology in heparan sulphate storing mucopolysaccharidoses.
    Derrick-Roberts A; Kaidonis X; Jackson MR; Liaw WC; Ding X; Ong C; Ranieri E; Sharp P; Fletcher J; Byers S
    Mol Genet Metab; 2020; 131(1-2):197-205. PubMed ID: 32739280
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy.
    Chen Y; Zheng S; Tecedor L; Davidson BL
    Mol Ther; 2018 Apr; 26(4):1118-1126. PubMed ID: 29503202
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Enzyme Replacement Therapy for Mucopolysaccharidosis IIID using Recombinant Human α-
    Wang F; Moen DR; Sauni C; Kan SH; Li S; Le SQ; Lomenick B; Zhang X; Ekins S; Singamsetty S; Wood J; Dickson PI; Chou TF
    Mol Pharm; 2021 Jan; 18(1):214-227. PubMed ID: 33320673
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P; Ketteridge D; Giugliani R; Guffon N; Teles EL; Miranda MC; Yu ZF; Swiedler SJ; Hopwood JJ;
    Pediatrics; 2005 Jun; 115(6):e681-9. PubMed ID: 15930196
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intravenous administration of human umbilical cord blood cells in an animal model of MPS III B.
    Garbuzova-Davis S; Klasko SK; Sanberg PR
    J Comp Neurol; 2009 Jul; 515(1):93-101. PubMed ID: 19399896
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Impact of chemical modification of sulfamidase on distribution to brain interstitial fluid and to CSF after an intravenous administration in awake, freely-moving rats.
    Janson J; Andersson G; Bergquist L; Eriksson M; Folgering JHA
    Mol Genet Metab Rep; 2020 Mar; 22():100554. PubMed ID: 31908953
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA.
    Gray AL; O'Leary C; Liao A; Agúndez L; Youshani AS; Gleitz HF; Parker H; Taylor JT; Danos O; Hocquemiller M; Palomar N; Linden RM; Henckaerts E; Holley RJ; Bigger BW
    Hum Gene Ther; 2019 Sep; 30(9):1052-1066. PubMed ID: 31020862
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Generation of a novel immunodeficient mouse model of Mucopolysaccharidosis type IIIA to test human stem cell-based therapies.
    Mandolfo O; Parker H; Usman A; Learmonth YI; Holley RJ; MacDonald A; McKay T; Bigger B
    Mol Genet Metab; 2024; 143(1-2):108533. PubMed ID: 39059269
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Hematopoietic stem cell and gene therapy corrects primary neuropathology and behavior in mucopolysaccharidosis IIIA mice.
    Langford-Smith A; Wilkinson FL; Langford-Smith KJ; Holley RJ; Sergijenko A; Howe SJ; Bennett WR; Jones SA; Wraith J; Merry CL; Wynn RF; Bigger BW
    Mol Ther; 2012 Aug; 20(8):1610-21. PubMed ID: 22547151
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Restoration of central nervous system alpha-N-acetylglucosaminidase activity and therapeutic benefits in mucopolysaccharidosis IIIB mice by a single intracisternal recombinant adeno-associated viral type 2 vector delivery.
    Fu H; DiRosario J; Kang L; Muenzer J; McCarty DM
    J Gene Med; 2010 Jul; 12(7):624-33. PubMed ID: 20603889
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome.
    Scott HS; Blanch L; Guo XH; Freeman C; Orsborn A; Baker E; Sutherland GR; Morris CP; Hopwood JJ
    Nat Genet; 1995 Dec; 11(4):465-7. PubMed ID: 7493035
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Purification and characterization of recombinant murine sulfamidase.
    Gliddon BL; Yogalingam G; Hopwood JJ
    Mol Genet Metab; 2004 Nov; 83(3):239-45. PubMed ID: 15542395
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.